Patient demographics and univariate analysis to identify risk for IRM
| Demographics . | All patients (n = 3126) . | IRM (n = 75 . | P-value (IRM vs all other patients) . |
|---|---|---|---|
| Sex | |||
| Female | 1350 (43.2%) | 39 (52.0%) | .1 |
| Male | 1776 (56.8%) | 36 (48.0%) | |
| Age group (age at treatment start), years | |||
| <2 | 210 (6.7%) | 5 (6.7%) | .5 |
| 2-9 | 2077 (66.4%) | 44 (58.7%) | .1* |
| 10-15 | 610 (19.5%) | 19 (25.3%) | |
| 16+ | 229 (7.3%) | 7 (9.3%) | |
| White blood cell group (×109/L) | |||
| <10 | 1407 (45.0%) | 31 (41.3%) | .1† |
| 10-19 | 502 (16.1%) | 7 (9.3%) | |
| 20-49 | 526 (16.8%) | 16 (21.3%) | |
| 50-99 | 315 (10.1%) | 9 (12.0%) | |
| 100+ | 376 (12.0%) | 12 (16.0%) | |
| NCI risk group | |||
| Standard | 1816 (58.1%) | 34 (45.3%) | .02 |
| High | 1310 (41.9%) | 41 (54.7%) | |
| DS | |||
| No | 3041 (97.2%) | 59 (78.7%) | <.0001 |
| Yes | 86 (2.8%) | 16 (21.3%) | |
| Immunophenotype | |||
| T | 387 (12.4%) | 8 (10.7%) | .6 |
| non-T | 2739 (87.6%) | 67 (89.3%) | |
| Treatment regimen given | |||
| A | 1538 (49.2%) | 27 (36.0%) | .01 |
| B | 845 (27.0%) | 31 (41.3%) | |
| C | 743 (23.8%) | 17 (22.7%) |
| Demographics . | All patients (n = 3126) . | IRM (n = 75 . | P-value (IRM vs all other patients) . |
|---|---|---|---|
| Sex | |||
| Female | 1350 (43.2%) | 39 (52.0%) | .1 |
| Male | 1776 (56.8%) | 36 (48.0%) | |
| Age group (age at treatment start), years | |||
| <2 | 210 (6.7%) | 5 (6.7%) | .5 |
| 2-9 | 2077 (66.4%) | 44 (58.7%) | .1* |
| 10-15 | 610 (19.5%) | 19 (25.3%) | |
| 16+ | 229 (7.3%) | 7 (9.3%) | |
| White blood cell group (×109/L) | |||
| <10 | 1407 (45.0%) | 31 (41.3%) | .1† |
| 10-19 | 502 (16.1%) | 7 (9.3%) | |
| 20-49 | 526 (16.8%) | 16 (21.3%) | |
| 50-99 | 315 (10.1%) | 9 (12.0%) | |
| 100+ | 376 (12.0%) | 12 (16.0%) | |
| NCI risk group | |||
| Standard | 1816 (58.1%) | 34 (45.3%) | .02 |
| High | 1310 (41.9%) | 41 (54.7%) | |
| DS | |||
| No | 3041 (97.2%) | 59 (78.7%) | <.0001 |
| Yes | 86 (2.8%) | 16 (21.3%) | |
| Immunophenotype | |||
| T | 387 (12.4%) | 8 (10.7%) | .6 |
| non-T | 2739 (87.6%) | 67 (89.3%) | |
| Treatment regimen given | |||
| A | 1538 (49.2%) | 27 (36.0%) | .01 |
| B | 845 (27.0%) | 31 (41.3%) | |
| C | 743 (23.8%) | 17 (22.7%) |